Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The aim of this study is to evaluate the efficacy and safety of intravitreal faricimab dosing interval at and beyond 24 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). This study is a retrospective case series of eight patients with persistent DME and nAMD who received intravitreal faricimab at and beyond the 24-week (6-month) dosing interval regimen. The majority of patients experienced an improved mean best-corrected visual acuity (BCVA) of 9.9 letters; congruent anatomical improvement (mean central macular thickness (CMT)) decrease of 44 m on optical coherence tomography (OCT) is demonstrated at 6 months despite extended faricimab dosing intervals. Extended intravitreal faricimab dosing intervals at and beyond 24 weeks maintained visual and anatomical outcomes in patients over 1 year. This suggests the feasibility of personalized extended dosing tailored to each patient's disease activity, potentially reducing treatment burden.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845267 | PMC |
| http://dx.doi.org/10.1155/crop/8843375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema in Japan.
Clin Ophthalmol
August 2025
Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Background: Diabetic macular edema (DME) is a leading cause of vision loss in working-age adults. Faricimab, a bispecific antibody targeting VEGF and Ang-2, has been shown to reduce treatment burden by enabling extended injection intervals. However, real-world, long-term data from Japanese populations are limited.
View Article and Find Full Text PDFSterile Intraocular Inflammation in Patients Receiving Both Faricimab and High-Dose Aflibercept in Consecutive Order.
J Vitreoretin Dis
August 2025
Retina Consultants P.C., Hartford, CT, USA.
To describe 3 cases of intraocular inflammation (IOI) in patients who received faricimab and high-dose aflibercept in consecutive order. Retrospective case review. Three patients, 2 with neovascular age-related macular degeneration (nAMD) and 1 with central retinal vein occlusion (CRVO), transitioned from 2 mg aflibercept to either faricimab (in cases 1 and 2) or high-dose aflibercept (in case 3) due to persistent disease activity.
View Article and Find Full Text PDFA Comparative Assessment of Intraocular Pressure Changes After Aflibercept 8 mg and Faricimab-svoa Intravitreal Injections in Wet Age-Related Macular Degeneration.
Cureus
July 2025
Medical Retina Service, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, GBR.
Introduction A standard practice for addressing wet age-related macular degeneration (WetAMD) is to deliver anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections. Formulations with higher concentrations, such as aflibercept 8 mg (Eylea HD; Bayer AG, Leverkusen, Germany), which are administered in larger volumes, may raise concerns about potential increases in intraocular pressure (IOP) and other ocular complications. The objective of this study was to evaluate and compare short-term IOP changes following intravitreal injection of aflibercept 8 mg (Eylea HD, 0.
View Article and Find Full Text PDFWe evaluated the efficacy of switching to intravitreal injection of faricimab (IVF) in patients with aflibercept-refractory neovascular age-related macular degeneration (nAMD) over 2 years of follow-up. We retrospectively reviewed 47 consecutive eyes of 45 Japanese patients with nAMD who switched from aflibercept to faricimab. Thirty-one eyes of 30 Japanese patients were included in this study.
View Article and Find Full Text PDFReal-World Clinical Experience With Monthly Faricimab for Treatment-Naïve Diabetic Macular Edema: A Case Series From an Indian Tertiary Care Center.
Cureus
July 2025
Department of Retina, Sarojini Devi Eye Hospital, Hyderabad, IND.
This case series explores the efficacy and safety of a monthly loading dose regimen of intravitreal faricimab in treatment-naïve patients with diabetic macular edema (DME) in an Indian clinical setting. In this retrospective analysis, five adult patients with treatment-naïve DME received faricimab (four intravitreal injections of 6 mg) on Day 0, Day 30, Day 60, and Day 90. Their best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated throughout the study.
View Article and Find Full Text PDF